Augmentation of fluoxetine's antidepressant action by pindolol: Analysis of clinical, pharmacokinetic, and methodologic factors

Journal of Clinical Psychopharmacology

Volumn 21, Issue 1, 2001, Pages 36-45

  Pérez, Victor ^a   Puigdemont, Dolors ^a   Gilaberte, Inmaculada ^b   Alvarez, Enric ^a   Artigas, Francesc ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b DCRandT   (Spain)

^c INST D INVESTIGACIONS B   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLOXACIN; PINDOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; METHODS; PINDOLOL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035141862     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200102000-00008     Document Type: Article

References (65)

1. Mood disorders in the general population represent an important and worldwide public health problem
2. Health care reform for Americans with severe mental illnesses: Report of the National Advisory Mental Health Council
3. The clinical meaning of refractory depression: A review for the clinician
4. Treatment of refractory mood disorders
5. NIMH treatment of depression collaborative research program
6. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat
7. Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants: Correlation with reduction of spontaneous firing rate of central monoaminergic neurones
8. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression
9. Differential effects of clomipramine given locally or systemically on extracellular 5-HT in raphe nuclei and frontal cortex
10. o proteins in dorsal raphe nucleus
11. 1A antagonist
12. 5-HT and antidepressants: New views from microdialysis studies
13. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
14. Effectiveness of pindolol with selected anti-depressant drugs in the treatment of major depression
15. Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression
16. Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy
17. 1A receptors induces rapid antidepressant response
18. Pindolol augmentation of tranylcypromine in psychotic depression
19. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression
20. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
21. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency
22. How long should pindolol be associated with paroxetine to improve the antidepressant response?
23. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study
24. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial
25. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance
26. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial
27. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors
28. Pindolol augmentation of treatment-resistant depressed patients
29. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors
30. Hippocampal atrophy in recurrent major depression
31. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity
32. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: Personality variables and response to paroxetine and pindolol
33. Fluoxetine: Clinical pharmacology and physiologic disposition
34. Pharmacokinetics of second generation antidepressants: Fluoxetine
35. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study
36. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression
37. Low-dose fluoxetine therapy for depression
38. Single and multiple dose pharmacokinetics of pindolol
39. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror
40. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies
41. Pindolol: A new beta-adrenoceptor antagonist with partial agonist activity
42. 1A autoreceptors in the action of selective serotonin reuptake inhibitors
43. 1A receptors
44. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5- hydroxytryptamine
45. 1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain
46. 1A) receptors
47. 1A ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain
48. Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: Preliminary analyses
49. Beta-blocker binding to the human 5-HT1A receptors in vivo and in vitro: Implications for antidepressant therapy
50. 1A receptors
51. 1A receptors in the rat brain
52. 1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: Single-unit study in unanesthetized, unrestrained rats
53. Increased antidepressant use in patients prescribed beta-blockers
54. Increased prescribing of antidepressants subsequent to β-blocker therapy
55. Chronic pindolol treatment and major affective disorders
56. Time course of the improvement under antidepressant treatment: A survival-analytical approach
57. Characterizing onset in psychopharmacological clinical trials
58. Are 2-week trials sufficient to indicate efficacy?
59. Justifying a "fast acting" claim for antidepressant drugs?
60. Survival analysis with unreliable endpoints
61. Speed of onset
62. The introductory placebo washout: A retrospective evaluation
63. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?
64. Placebo run-in period in studies of depressive disorders